UBX241220C3000
- 0.05
- 0.000.00%
Unity Biotechnology Newsroom
Unity Biotechnology Focuses on Promising DME Treatment
Unity Biotechnology GAAP EPS of -$0.38 Beats by $0.02
Express News | Unity Biotechnology Q3 2024 GAAP EPS $(0.38) Beats $(0.40) Estimate
Unity Biotechnology | 10-Q: Q3 2024 Earnings Report
Unity Biotechnology | 8-K: UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
Express News | UNITY Biotechnology Inc: UNITY Expects Topline 24-Week Primary Endpoint Data in Q1 of 2025 and 36-Week Data in Q2 of 2025
Unity Biotechnology 3Q Loss/Shr 38c >UBX
Press Release: UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
Express News | UNITY Biotechnology Q3 Net Income USD -6.481 Million
Express News | UNITY Biotechnology Q3 Operating Expenses USD 6.602 Million
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
Hard Rock and John Legend 'Come Together for Good' at Special Performance for Unity by Hard Rock Members
Rodman & Renshaw Maintains Unity Biotechnology(UBX.US) With Buy Rating, Cuts Target Price to $8
Express News | Rodman & Renshaw Initiates Coverage On Unity Biotechnology With Buy Rating, Announces Price Target of $8
UNITY Biotechnology to Participate in Upcoming Investor Conferences
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
Unity Biotechnology Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Foselutoclax Trial Results and Strong Financial Position
Unity Biotechnology | 10-Q: Q2 2024 Earnings Report
Unity Biotechnology | 8-K: UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates